scientific output

2026

Barry-Simonnet C, Crouzier L, Moujellil-Legagneur T, Chaieb-Errass H, Idres YA, Ferrare K, Rolland M, Cazals G, Poucheret P, Maurice T, Tousch D. Xanthatin-13-(Pyrrolidine-2-Carboxylic Acid), a Sesquiterpene Lactone Isolated From Burdock Leaf, Attenuated Aβ25-35 Toxicity and Memory Deficits in a Pharmacological Mouse Model of Alzheimer’s Disease. Phytother Res. 2026 Mar 7. doi: 10.1002/ptr.70294.

Coste J, Carcaillon-Bentata L, Robine JM, Trouvin AP, Humphreys J, Guillemin F. Trends in the prevalence and disability burden of major rheumatic and musculoskeletal diseases in France, 2008–2022. RMD Open. May 11, 2026;12(2):e006584. doi: 10.1136/rmdopen-2025-006584.

RBlanch R, Esandi J, Guerrero-Yagüe R, del Rey J, Roig-Soriano J, Lleo A, Carro E, Mestre-Francés N, Devau G, Ferrer I, Meseguer A, Lanciego JL, Almolda B, Bosch B, Chillón M. sKL/mKL Transcript Ratio and Protein Localization Define a Species- and Region-Specific Klotho Signature in the CNS and AD Progression. Genes and Diseases 2026 (accepted)

Grasso M, Moser PO, Sauvageot S, Gil V, Chan-Seng E, Sanrey E, Coubes P, Poulen G. Putamen Atrophy as a Predictive Factor of Efficacy of GPi-DBS in Dystonia-Dyskinesia Syndrome Secondary to Perinatal Anoxic Encephalopathy. Mov Disord. 2026 Mar 18. doi: 10.1002/mds.70275.

Grasso M, Coelho C, Chan-Seng E, Coubes P, Poulen G. Perinatal Post-Anoxic Spinal Cord Injury: A Barrier to Pallidal Neuromodulation? A Report on 2 Cases. Mov Disord Clin Pract. 2026 Mar 20. doi: 10.1002/mdc3.70602.

Gazard CM, Poulen G, Perrin FE. Glial heterogeneity in the primate spinal cord: Implications of age and sex differences for neurodegenerative and neurotraumatic diseases. Neural Regen Res. January 27, 2026. doi: 10.4103/NRR.NRR-D-25-01274.

Mastropasqua F, Lisi AT, Crouzier L, Musillo GR, Abatematteo FS, Niso M, Delprat B, Colabufo NA, Nanna V, Mangiatordi GF, Delre P, Spalholz T, Colella M, Deuther-Conrad W, Loiodice F, Maurice T, Laghezza A, Abate C. Development of Second-Generation Phenoxyethylpiperidines as Potent Sigma-1 Receptor Agonists with Neuroprotective Potential for Alzheimer’s Disease. J Med Chem. 2026 Feb 26;69(4):4613-4628. doi: 10.1021/acs.jmedchem.5c03240.

Marelli C, Charret Q, Goizet C, Thevenon J, Bernard V, Ory Magne F, Degoutin M, Fergelot P, Renaud M, Koenig M, Ramond F. STUB1 (SCA48)/TBP (SCA17): A Frequent Association Still Not Fully Explained and a Lower Threshold for Intermediate Expanded TBP Alleles. Mov Disord. 2026 Mar 27. doi: 10.1002/mds.70296.

Otaegui L, Lehoux J, Begu S, Moujellil-Legagneur T, Zussy C, Vitalis M, Mathias M, Beau A, Durand T, Givalois L, Bernoud-Hubac N, Crauste C, Desrumaux C. Intranasal administration of lipid nanocapsules containing the new lipophenol quercetin-3-O-DHA-7-O-iPr reduces carbonyl stress and improves behavior in a mouse model of Alzheimer’s disease. Drug Deliv Transl Res. May 6, 2026. doi: 10.1007/s13346-026-02142-5.

Reichau K, Crouzier L, Poeta E, Gehrig T, Schaller E, Zvejniece L, Meunier J, Sotriffer C, Monti B, Maurice T, Decker M. A Dual Approach to Combat Alzheimer’s Disease through Concomitant hBChE Inhibition and S1R Activation. ACS Chem Neurosci. 2026 Feb 18;17(4):805-822. doi: 10.1021/acschemneuro.5c00921.

Reichau K, Crouzier L, Gehrig T, Flake A, Schaller E, Meunier J, Bertrand-Gaday C, Chatonnet A, Zvejniece L, Sotriffer C, Maurice T, Decker M. Targeting neuroinflammation by activation of the sigma-1 receptor (S1R) and inhibition of butyrylcholinesterase (hBChE) leads to highly potent anti-amnesic compounds in an Alzheimer’s disease mouse model. Eur J Med Chem. 2026 Mar 5;305:118486. doi: 10.1016/j.ejmech.2025.118486.

Sałaciak K, Lustyk K, Jagielska A, Szafarz M, Inteiro-Oliveira S, Diógenes MJ, Xapelli S, Schnur P, Morton L, Moran E, Ferreira J, Sakata S, Crouzier L, Meunier J, Delprat B, Maurice T, Pytka K. The Sigma-1-targeting multimodal compound HBK-15 reverses memory deficits and restores hippocampal plasticity under NMDA hypofunction. Neurotherapeutics. January 2026;23(1):e00774. doi: 10.1016/j.neurot.2025.e00774.

Travers-Lesage V, Crouzier L, Antonijevic M, Wang A, Toublet FX, Davis A, Modeste F, Brazzolotto X, Nachon F, Since M, Maurice T, Rochais C, Dallemagne P. Access to novel potent pleiotropic prodrugs, targeting both butyrylcholinesterase and serotonin reuptake, with anti-amnesic activities in an Alzheimer’s disease model. Eur J Med Chem. 2026 Apr 5;307:118670. doi: 10.1016/j.ejmech.2026.118670.